Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

H Lee Moffitt Cancer Center And Research Institute Inc patents


Recent patent applications related to H Lee Moffitt Cancer Center And Research Institute Inc. H Lee Moffitt Cancer Center And Research Institute Inc is listed as an Agent/Assignee. Note: H Lee Moffitt Cancer Center And Research Institute Inc may have other listings under different names/spellings. We're not affiliated with H Lee Moffitt Cancer Center And Research Institute Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | H Lee Moffitt Cancer Center And Research Institute Inc-related inventors


Bone fusion system

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed. The screw includes a threaded distal piece fixedly attached connected to an inner post. Both the inner post and the proximal piece have non-cylindrical receptacles at their proximal ends for... H Lee Moffitt Cancer Center And Research Institute Inc

Combination immunotherapy for small cell lung cancer

A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA).... H Lee Moffitt Cancer Center And Research Institute Inc

Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds

Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.... H Lee Moffitt Cancer Center And Research Institute Inc

Histology recognition to automatically score and quantify cancer grades and individual user digital whole histological imaging device

Digital pathology is the concept of capturing digital images from glass microscope slides in order to record, visualize, analyze, manage, report, share and diagnose pathology specimens. The present disclosure is directed to a desktop slide scanner, which enables pathologists to scan slides at a touch of a button. Included is... H Lee Moffitt Cancer Center And Research Institute Inc

Method of developing a vaccine using peptide-poly ic complexes

The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer and their administration to a subject in order to elicit a T cell response in the subject. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified... H Lee Moffitt Cancer Center And Research Institute Inc

Inflammasome activation in myelodysplastic syndromes

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of an inflammasome inhibitor. Also disclosed are methods for diagnosing a myelodysplastic syndrome (MDS) in a subject. In some embodiments, the method involves assaying a sample from the... H Lee Moffitt Cancer Center And Research Institute Inc

Bone fusion system

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed. The screws include a threaded tip connected to a main shaft and a threaded outer sleeve that rotates relative to the outer shaft until locked down. Independent rotation of the... H Lee Moffitt Cancer Center And Research Institute Inc

Methods of treating cognitive impairment

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3... H Lee Moffitt Cancer Center And Research Institute Inc

Selective histone deactylase 6 inhibitors

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

Bromodomain inhibitor as adjuvant in cancer immunotherapy

Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject... H Lee Moffitt Cancer Center And Research Institute Inc

Systems, methods and devices for analyzing quantitative information obtained from radiological images

An example method for analyzing quantitative information obtained from radiological images includes identifying a ROI or a VOI in a radiological image, segmenting the ROI or the VOI from the radiological image and extracting quantitative features that describe the ROI or the VOI. The method also includes creating a radiological... H Lee Moffitt Cancer Center And Research Institute Inc

Arterial catheters and methods of use

Provided herein are systems, devices and methods for catheterization including arterial catheterization. An arterial catheter system, comprising a) a flexible tube sized for insertion into the artery of a subject defining at least one channel, b) a chamber portion connected at its distal end to the flexible tube, wherein the... H Lee Moffitt Cancer Center And Research Institute Inc

Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.... H Lee Moffitt Cancer Center And Research Institute Inc

Pet probes of radiofluorinated carboximidamides for ido-targeted imaging

18F labeled IDO1 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a 1-fluoro-2-halo-4-aminobenzene and a 4-amino-N-hydroxy-1,2,5-oxadiazole-3-carboximidoyl chloride wherein at least one of the coupled compounds comprises an 18F. The 18F labeled IDO1 imaging constructs are useful for imaging cancer cells in a patient.... H Lee Moffitt Cancer Center And Research Institute Inc

Tlr9 targeted cytotoxic agents

Disclosed are compositions and methods for targeted treatment of TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target cytotoxic agents to TLR9-expressing malignant cells are disclosed. Compositions and methods are disclosed for targeted treatment of cancer or cancer-stem cells with extracellular TLR9... H Lee Moffitt Cancer Center And Research Institute Inc

Tetravalent tlr9 bispecific antibody

Disclosed are compositions and methods for targeted treatment of TLR9-expressing cancers, such as primary human MDS progenitors and hematopoietic stem cell (HSC), as well as lung and breast cancers. In particular, multispecific, multivalent antibodies are disclosed that are able to engage T-cells to destroy TLR9-expressing malignant cells.... H Lee Moffitt Cancer Center And Research Institute Inc

Phosphorylation of histones and uses thereof

Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr 51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are... H Lee Moffitt Cancer Center And Research Institute Inc

Supervised learning methods for the prediction of tumor radiosensitivity to preoperative radiochemotherapy

Disclosed is a gene expression panel that can predict radiation sensitivity (radiosensitivity) of a tumor in a subject. A method of predicting radiation sensitivity is provided that is based on cellular clonogenic survival after 2 Gy (SF2) for 48 cell lines. Gene expression is used as the basis of the... H Lee Moffitt Cancer Center And Research Institute Inc

Potent dual brd4-kinase inhibitors as cancer therapeutics

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.... H Lee Moffitt Cancer Center And Research Institute Inc

Melanocortin 1 receptor ligands and methods of use

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click... H Lee Moffitt Cancer Center And Research Institute Inc

Expandable intervertebral cage

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.... H Lee Moffitt Cancer Center And Research Institute Inc

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The... H Lee Moffitt Cancer Center And Research Institute Inc

Conjugates for immunotherapy

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a... H Lee Moffitt Cancer Center And Research Institute Inc

Radiotherapy targeted to promote a systemic abscopal effect

Methods for personalized treatment of tumor lesions in subject with metastatic cancer are disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

Stabilized peptoid-peptide hybrids and uses thereof

The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.... H Lee Moffitt Cancer Center And Research Institute Inc

Immune gene signatures in urothelial carcinoma (uc)

This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.... H Lee Moffitt Cancer Center And Research Institute Inc

Materials and methods for differential treatment of cancer

The present invention concerns differential therapeutic treatment of cancer patients based on prognostic antigen/antibody profiles used for predicting (prognosticating) a clinical response (efficacy) and/or adverse event to an immunotherapy for treatment of a malignancy in a subject, and for treating or delaying the onset or relapse of a malignancy in... H Lee Moffitt Cancer Center And Research Institute Inc

Gamma-aa-peptide stat3/dna inhibitors and methods of use

STAT3 hyperphosphorylation, dimerization and DNA binding are required for its ability to contribute to malignant transformation. As such, STAT3 has been recognized as a promising target for cancer therapy. Although a number of inhibitors of STAT3-STAT3 dimerization have been reported, molecular ligands that prevent interactions between STAT3 and DNA are... H Lee Moffitt Cancer Center And Research Institute Inc

Tumor-infiltrating lymphocytes for adoptive cell therapy

Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes... H Lee Moffitt Cancer Center And Research Institute Inc

Radiologically identified tumor habitats

Virtually every cancer patient is imaged with CT, PET or MRI. Importantly, such imaging reveals that tumors are complex and heterogeneous, often containing multiple habitats within them. Disclosed herein are methods for analyzing these images to infer cellular and molecular structure in each of these habitats. The methods can involve... H Lee Moffitt Cancer Center And Research Institute Inc

Evidence-based clinical decision system

Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, including a system for providing treatment suggestions. The system includes a data warehouse including patient data for a plurality of patients associated with one or more care facilities, and one or more processors including instructions for implementing... H Lee Moffitt Cancer Center And Research Institute Inc

Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination

Disclosed are methods whereby an effective amount of a HDAC6 inhibitor is used to activate a subjects T-cell response to tumor or tumor vaccine. Methods of using HDAC6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

Bispecific antibody for cancer immunotherapy

Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells. Disclosed are bispecific antibodies that are able to engage T-cells to destroy TAG-72-expressing malignant cells. The antibodies can be engineered from fusion... H Lee Moffitt Cancer Center And Research Institute Inc

Histone deacetylase as a modulator of pdl1 expression and activity

Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective... H Lee Moffitt Cancer Center And Research Institute Inc

02/23/17 / #20170049760

Inhibitors of rho associated protein kinases (rock) and methods of use

Compounds and compositions having activity as inhibitors of Rho-associated proteinkinases (ROCKs), and methods of making and using the subject compounds are disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

02/23/17 / #20170050981

Marinopyrrole derivatives and methods of making and using same

Marinopyrrole derivatives and methods for their synthesis and use are described herein. Novel cyclic and symmetric marinopyrroles with triazole substituents having antibacterial activity against resistant bacterial strains, such as MRSA are introduced. Also provided are methods of using the compounds for treating or preventing cancer and/or microbial infections.... H Lee Moffitt Cancer Center And Research Institute Inc

02/16/17 / #20170044127

Icariin derivatives

Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-VIII as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

02/16/17 / #20170044496

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity.... H Lee Moffitt Cancer Center And Research Institute Inc

02/09/17 / #20170035710

Selective histone deactylase 6 inhibitors

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

02/02/17 / #20170027893

Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof

Lysophosphatidic acid acyltransferase-beta (LPAAT-β) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-ζ. LPAAT-β expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of... H Lee Moffitt Cancer Center And Research Institute Inc

02/02/17 / #20170029902

Determining prostate cancer recurrence using polymorphisms in angiogenesis-related genes

In particular, disclosed is a method for treating a patient with prostate cancer that involves genotyping a nucleic acid sample from the subject for one or more single nucleotide polymorphism (SNP) alleles in one or more genes angiogenesis, comparing the one or more SNP alleles to control allele frequencies to... H Lee Moffitt Cancer Center And Research Institute Inc

01/26/17 / #20170022571

Microrna assay for detection and management of pancreatic cancer precursors

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In... H Lee Moffitt Cancer Center And Research Institute Inc

01/05/17 / #20170000787

Aurora kinase inhibitors and methods of making and using thereof

Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.... H Lee Moffitt Cancer Center And Research Institute Inc

01/05/17 / #20170002423

Microrna signature for predicting progression of barrett's esophagus

Biomarkers, methods, assays, and kits are provided for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. Disclosed are methods for predicting the progression of Barrett esophagus in... H Lee Moffitt Cancer Center And Research Institute Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with H Lee Moffitt Cancer Center And Research Institute Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for H Lee Moffitt Cancer Center And Research Institute Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###